Bipolar disorder treatment for Pompano Beach — the diagnosis primary care misses.

RECO Integrated Psychiatry sits 18 miles north of Pompano Beach on I-95 — about 28 minutes from Cresthaven or Lighthouse Point. Bipolar disorder is treated by a board-certified psychiatrist across the full pharmacologic range: lithium with structured level and thyroid monitoring, lamotrigine titrated safely to 200 mg, quetiapine and lurasidone for bipolar depression, and valproate for mania. Diagnosis is committed to only after MDQ, HCL-32, and structured hypomania history — because misclassifying bipolar depression as unipolar drives most treatment failures.

The 18-mile trip north on I-95 from Pompano Beach to RECO Integrated Psychiatry’s Delray Beach office runs about 28 minutes outside rush hour. For adults living in Cresthaven, Lighthouse Point, Sea Ranch Lakes, or Hillsboro Shores, that distance is far enough to give clinical work a container separate from daily life yet close enough to keep pharmacy pickups, work schedules, and family routines intact. Bipolar disorder is an episodic illness that rewards consistent follow-up over years, and a specialist psychiatric practice within the same broader South Florida community is more sustainable than a residential detour.

Bipolar I, bipolar II, and bipolar spectrum are pharmacologically different illnesses

Bipolar I is defined by a manic episode — seven days or more of elevated or irritable mood with associated symptoms, or any duration if hospitalization is required. Bipolar II requires a hypomanic episode plus a major depressive episode. Bipolar spectrum captures cyclothymia, BP-NOS, subthreshold hypomania, and antidepressant-induced hypomania: presentations with clear cyclicity that do not meet full DSM-5 criteria. Distinguishing the three is the load-bearing part of the evaluation, and misclassifying bipolar depression as unipolar major depressive disorder drives most of the treatment failures referred in.

The distinction changes the pharmacology. Bipolar I typically responds to a mood stabilizer combined with a second-generation antipsychotic. Bipolar II depression responds well to lamotrigine and quetiapine and less predictably to lithium monotherapy. Bipolar spectrum presentations require careful use of antidepressants only under adequate mood stabilizer cover, because unopposed SSRIs and SNRIs can precipitate switch into mania or induce rapid cycling.

RECO’s diagnostic protocol pairs the Mood Disorder Questionnaire (MDQ) and the Hypomania Checklist-32 (HCL-32) with structured hypomania history-taking, family psychiatric history, and — where the picture is ambiguous — several weeks of daily mood charting before a bipolar diagnosis is committed to. A PHQ-9 and GAD-7 baseline runs alongside to track depressive and anxious features longitudinally across visits.

Lithium: the treatment we take seriously when other practices avoid it

Lithium remains the most effective long-term mood stabilizer in bipolar disorder and the only psychiatric medication with robust evidence for reducing suicide. It is not a drug to prescribe casually — baseline TSH, creatinine, calcium, and CBC are required before initiation, target maintenance serum level is 0.6-1.0 mEq/L, and levels are drawn quarterly during the first year and semiannually thereafter, along with periodic thyroid and renal panels.

Many clinicians avoid lithium because the monitoring feels operationally burdensome and because tremor, thirst, weight gain, and thyroid effects require active management rather than passive prescribing. RECO’s protocol builds the monitoring in: labs are ordered on schedule, results are reviewed at each visit, and dose is adjusted to keep levels inside the therapeutic window. For clients who tolerate lithium, the reduction in episode frequency and the suicide-protective effect justify the operational load.

Second-generation antipsychotics and where they fit

Each FDA-approved second-generation antipsychotic in bipolar disorder carries a specific indication set. Quetiapine covers bipolar depression, acute mania, and maintenance. Lurasidone is approved for bipolar depression with a favorable metabolic profile. Aripiprazole and cariprazine are approved for mania and maintenance; risperidone for mania. Olanzapine and the olanzapine-fluoxetine combination cover bipolar depression and mania at the cost of the heaviest metabolic burden in the class.

Choice is driven by the current phase of illness, prior response history, and tolerability profile. Weight, waist circumference, fasting glucose or HbA1c, lipid panel, and blood pressure are checked at baseline and at 3-, 6-, and 12-month intervals in line with APA guidance, and metabolic side effects are addressed proactively rather than after a client has gained 30 pounds and developed dyslipidemia.

Lamotrigine, valproate, and the anticonvulsant mood stabilizers

Lamotrigine has the strongest evidence base for bipolar II depression and for maintenance treatment when the depressive pole predominates. Titration is deliberately slow — 25 mg for two weeks, 50 mg for two weeks, 100 mg for one week, then 200 mg — to keep the risk of Stevens-Johnson syndrome and DRESS below population baseline. Any rash during titration is treated as a stop event pending clinical evaluation.

Valproate is effective in acute mania and mixed states. Monitoring includes LFTs, CBC with platelets, and valproate serum levels targeting 50-125 mcg/mL; women of reproductive potential are counseled on teratogenicity and pregnancy planning before initiation, not after. Carbamazepine remains a second-line option for lithium- and valproate-nonresponsive mania, with attention to autoinduction, HLA-B*1502 screening in at-risk populations, and drug-drug interactions through CYP3A4.

These medications are not interchangeable. Matching the anticonvulsant to the presentation — depressive-predominant, manic-predominant, mixed, or rapid-cycling — is a decision that pays off across years of maintenance rather than weeks.

What the first visit looks like

The initial evaluation runs 60-90 minutes with a board-certified psychiatrist. A structured longitudinal history is collected covering age at first mood episode, episode count and character, prior medication trials with doses and durations, response and side-effect data, family psychiatric history, substance use, sleep architecture, and current stressors. Screening instruments (MDQ, HCL-32, PHQ-9, GAD-7, and where indicated the ASRS for adult ADHD) are administered and scored during the visit.

A working diagnosis and treatment plan are discussed at the end of the intake, along with lab orders where a mood stabilizer or antipsychotic is being started or adjusted. Follow-up is typically two to four weeks during titration and monthly to quarterly once stable. When indicated, referrals to therapists trained in interpersonal and social rhythm therapy (IPSRT), family-focused therapy for bipolar disorder, or CBT adapted for bipolar are coordinated directly rather than handed off as a list.

Insurance, telepsychiatry, and getting to Delray Beach from Pompano

RECO Integrated Psychiatry is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans held across Broward and Palm Beach counties. Benefits are verified before intake so out-of-pocket cost is known up front. For Pompano Beach clients, follow-up visits are frequently conducted by telepsychiatry once the diagnosis is settled and the regimen is stable, keeping the 28-minute drive to a quarterly or biannual event tied to in-person labs and clinical review. Clients who prefer in-person visits throughout are welcome to do so — bipolar disorder treatment at RECO is delivered by the same psychiatrist across both formats.

Serving residents of: Cresthaven, Lighthouse Point, Sea Ranch Lakes, Hillsboro Shores.